Noopept tablets 10mg, No. 50

Impaired memory, attention, other cognitive functions and emotionally labile disorders (including in elderly patients) with:

• consequences of traumatic brain injury

• post-concussion syndrome

• cerebrovascular insufficiency (encephalopathies of various origins)

• asthenic disorders

• other conditions with signs of decreased intellectual productivity.

NoopeptЃ is applied orally, after meals. Treatment begins with the use of the drug in a dose of 20 mg, distributed in 10 mg divided into two doses during the day (morning and afternoon). In case of insufficient effectiveness of therapy and if the drug is well tolerated, the dose of NoopeptЃ is increased to 30 mg (see 'Special Instructions'), distributed at 10 mg in three doses during the day. Do not take the drug later than 18 hours. The duration of the course of treatment is 1.5-3 months. A repeated course of treatment, if necessary, can be carried out after 1 month.

Each tablet contains:
Active ingredient: NoopeptЃ -10 mg.
Excipients: microcrystalline cellulose, lactose (milk sugar), potato starch, povidone, magnesium stearate.

Pregnancy, lactation. Age under 18.

Individual intolerance to the drug. Severe liver and kidney dysfunctions.

Trade name of the drug: NoopeptЃ

Chemical rational name: N-phenylacetyl-L-prolylglycine ethyl ester.

Dosage form:

pills.

Composition
Each tablet contains:
Active ingredient: NoopeptЃ -10 mg.
Excipients: microcrystalline cellulose, lactose (milk sugar), potato starch, povidone, magnesium stearate.

Description: tablets of white color, flat-cylindrical with a facet.

Pharmacotherapeutic group:

nootropic agent.

ATX code: [N06BX].

Pharmacological action
NoopeptЃ is a nootropic drug with nootropic and neuroprotective properties. Improves learning ability, memory, acting on all phases of processing: initial information processing, consolidation, extraction. Prevents the development of amnesia caused by electroshock, blockade of central cholinergic structures, glutamatergic receptor systems, deprivation of the paradoxical phase of sleep.
The neuroprotective (protective) effect of NoopeptЃ is manifested in an increase in the resistance of the brain tissue to damaging influences (trauma, hypoxia, electroconvulsive, toxic) and in weakening the degree of damage to brain neurons. The drug reduces the volume of the focus in the thrombotic model of stroke and prevents the death of neurons in the tissue culture of the cerebral cortex and cerebellum exposed to neurotoxic concentrations of glutamate and free radical oxygen.
NoopeptЃ has an antioxidant effect, antagonistic effect on the effects of excess calcium, improves the rheological properties of blood, having antiaggregatory, fibrinolytic, anticoagulant properties. The nootropic effect of the drug is associated with the formation of cycloprolylglycine, which is similar in structure to an endogenous cyclic dipeptide with antiamnestic activity, as well as with the presence of a cholinopositive action.
NoopeptЃ increases the amplitude of the transcallosal response, facilitating associative connections between the cerebral hemispheres at the level of cortical structures. NoopeptЃ promotes the restoration of memory and other cognitive functions impaired as a result of damaging influences - brain trauma, local and global ischemia, prenatal injuries (alcohol, hypoxia).
The therapeutic effect of the drug in patients with organic disorders of the central nervous system is manifested starting from 5-7 days of treatment. Initially, the anxiolytic and mild stimulating effects available in the spectrum of NoopeptЃ activity are realized, manifested in the reduction or disappearance of anxiety, increased irritability, affective lability, and sleep disturbances. After 14-20 days of therapy, a positive effect of the drug on cognitive functions, attention and memory parameters is revealed.
NoopeptЃ has a vegetative-normalizing effect, helps to reduce headaches, orthostatic disorders, and tachycardia.
NoopeptЃ does not accumulate in the body, does not cause drug dependence. When the drug is discontinued, there is no withdrawal syndrome.
Noopept has no damaging effect on internal organs, does not lead to a change in hematological and biochemical parameters; does not possess immunotoxic, teratogenic effects, does not exhibit mutagenic properties.

Pharmacokinetics
NoopeptЃ, being absorbed in the gastrointestinal tract, enters the systemic circulation unchanged, penetrates the blood-brain barrier, is determined in the brain in higher concentrations than in the blood. The time to reach the maximum concentration is on average 15 minutes. The half-life from blood plasma is 0.38 hours. The drug is partially preserved unchanged, partially metabolized to form phenylacetic acid, phenylacetylproline and cycloprolylglycine. It has a high relative bioavailability (99.7%).

Indications for use
Impaired memory, attention, other cognitive functions and emotionally labile disorders (including in elderly patients) with:

• consequences of traumatic brain injury

• post-concussion syndrome

• cerebrovascular insufficiency (encephalopathies of various origins)

• asthenic disorders

• other conditions with signs of decreased intellectual productivity.

Contraindications
Pregnancy, lactation. Age under 18.

Individual intolerance to the drug. Severe liver and kidney dysfunctions.

Method of administration and dosage
NoopeptЃ is administered orally, after meals. Treatment begins with the use of the drug in a dose of 20 mg, distributed in 10 mg divided into two doses during the day (morning and afternoon). In case of insufficient effectiveness of therapy and if the drug is well tolerated, the dose of NoopeptЃ is increased to 30 mg (see 'Special Instructions'), distributed at 10 mg in three doses during the day. Do not take the drug later than 18 hours. The duration of the course of treatment is 1.5-3 months. A repeated course of treatment, if necessary, can be carried out after 1 month.

Side effects
Allergic reactions are possible. In patients with arterial hypertension, mainly of severe degree, while taking the drug, an increase in blood pressure may be observed.

Overdose
Specific manifestations of overdose have not been established. Interaction with other drugs The interaction of NoopeptЃ with alcohol, hypnotics and antihypertensive drugs and psychostimulating drugs has not been established.

Special instructions
If it is necessary to increase the dose of the drug (up to 30 mg / day), with prolonged use, as well as with simultaneous use with other drugs, the appearance of adverse reactions or worsening of the condition, you should consult a doctor.

Release form
25 tablets in a blister strip made of polyvinyl chloride film and lacquered aluminum foil.
30 or 50 tablets in polymer cans with tamper evident control.
One can or 2 blisters together with instructions for use in a cardboard box.

Storage conditions
List B.
In a dry, dark place at a temperature not exceeding + 25 ? C.
Keep out of the reach of children.

Shelf life is
2 years. Do not use later than the date indicated on the package.

Terms of dispensing from pharmacies:

without a doctor's prescription.